Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06298864
Other study ID # ASC-RCT 2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 10, 2024
Est. completion date January 31, 2027

Study information

Verified date June 2024
Source Karolinska Institutet
Contact Josefin Särnholm, Lic psychologist, PhD
Phone + 46 852483258
Email josefin.sarnholm@ki.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate if an online Cognitive Behavioral Therapy (CBT) protocol customized for patients following Acute Coronary Syndrome (ACS), reduce cardiac anxiety, enhance Quality of Life (QoL), and promote increased physical activity while controlling for caregiver attention, utilizing an active control group receiving internet-based cardiac lifestyle intervention.


Description:

ACS is a leading global cause of mortality and health-related losses. Following ACS, many individuals exhibit symptoms of anxiety and depression, recognized risk factors for recurrent cardiovascular events. Specifically, anxiety related to cardiac symptoms and avoidance behavior, known as cardiac anxiety, has been shown to increase the long-term risk of adverse cardiac events. The purpose of the present interdisciplinary research project is to develop and evaluate an online CBT protocol tailored for ACS patients. This project comprises a series of clinical studies aimed at accumulating knowledge about the most effective ways to treat ACS patients with CBT over the internet. The aim of this study is to assess whether internet-based CBT, following ACS, reduces cardiac anxiety and improves QoL, while controlling for caregiver attention and expectancy of improvement using an active control group. Method: A randomized controlled trial is conducted where participants are randomly assigned to either internet-based CBT (N=130) or internet-based cardiac lifestyle intervention (internet-CL) (N=130). The active control group receives internet-CL, focusing on lifestyle modification and health-promoting behaviors. Weekly therapist support through online written communication is provided to participants in both groups. Both treatment are conducted over 8-weeks and are comparable in terms of the number of treatment modules, intensity, and attention from the treating psychologist.


Recruitment information / eligibility

Status Recruiting
Enrollment 260
Est. completion date January 31, 2027
Est. primary completion date January 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ACS = 6 months before assessment (type 1 MI STEMI/NSTEMI or unstable angina [UA]) - Age 18 and older - Clinically significant cardiac anxiety that leads to distress and/or interferes with daily life (Cardiac Anxiety Questionnaire; CAQ: =18 - Able to read and write in Swedish Exclusion Criteria: - Heart failure New York heart Association class IV or ejection fraction = 30% - Significant valvular disease - Planned coronary artery bypass surgery or percutaneous interventions - Any medical restriction to physical exercise - Severe medical illness or an acute health threatening disease (e.g., cancer) - Grade 3 hypertension (i.e., blood pressure = 180 systolic and/or 110 diastolic) - Severe mental illness requiring urgent psychiatric hospitalization or intervention, or risk of suicide - Alcohol or substance use disorder that would impede ability to complete study protocol - Ongoing psychological treatment

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Internet-CBT
Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet. Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them. Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity. Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle.
Internet-CL
Education on ACS, risk factors, its treatments and medication. Education and advice promoting healthy habits regarding diet, alcohol and tobacco. Education and advice regarding physical activity and the beneficial effects on health. Education regarding common emotional reactions following ACS. Prevention of relapse and plan forward to maintain a healthy lifestyle.

Locations

Country Name City State
Sweden Karolinska University Hospital Stockholm

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Karolinska University Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events Potential adverse reactions to the treatment. Participants will be asked to report and rate Baseline to 8 weeks
Other Adverse events Potential adverse reactions to the treatment. Participants will be asked to report and rate Baseline to 8 months
Other Adverse events Potential adverse reactions to the treatment. Participants will be asked to report and rate Baseline to 1 year and 2 months
Other Adverse events Potential adverse reactions to the treatment. Participants will be asked to report and rate Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment
Other Accelerometer (Actigraf®) n Accelerometer (Actigraf®) will be carried on the wrist over to measure physical activity over 1 week Baseline to 8 weeks
Other Accelerometer (Actigraf®) n Accelerometer (Actigraf®) will be carried on the wrist over to measure physical activity over 1 week Baseline to 1 year and 2 months
Other Swedish Prescribed Drug Register The prescription fill-rate of cardiovascular medication (e.g., statin)will be collected and will be used to calculate the proportion of days covered (PDC) with a statin. A PDC <80% will be used to indicate nonadherence as per convention in other studies of cardiovascular medication refills. Retrospective period of 6 months at baseline
Other Swedish Prescribed Drug Register The prescription fill-rate of cardiovascular medication (e.g., statin)will be collected and will be used to calculate the proportion of days covered (PDC) with a statin. A PDC <80% will be Retrospective period from 6 months at 6 month follow up
Other Swedish Prescribed Drug Register The prescription fill-rate of cardiovascular medication (e.g., statin)will be collected and will be used to calculate the proportion of days covered (PDC) with a statin. A PDC <80% will be Retrospective period from 6 months at 12 month follow up
Other Working Alliance Inventory Measures therapeutic alliance with the psychologist 2 weeks from baseline
Other Treatment Credibility Scale 2 weeks from baseline Measures treatment credibility
Other Client satisfaction Questionnaire Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment. Baseline to 8 weeks
Other Follow-up questions on health changes We will ask participant to describe if they have experienced any psychosocial stressors, changes in physical health, such as invasive therapy and changes of medication Baseline to 8 weeks
Other Follow-up questions on health changes We will ask participant to describe if they have experienced any psychosocial stressors, changes in physical health, such as invasive therapy and changes of medication Baseline to 8 months
Other Follow-up questions on health changes We will ask participant to describe if they have experienced any psychosocial stressors, changes in physical health, such as invasive therapy and changes of medication Baseline to 1 year and 2 months
Other AFFS/SCL-4 4 items derived from the Symptoms Checklist (SCL) and the Atrial Fibrillation Severity Scale (AFSS) measuring disabling cardiac symptoms Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment
Other MI-behavior Questionnaire 5 items measuring avoidance behavior from the MI-related avoidance questionnaire behaviors developed by the research group Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment
Other DOSE Non-Adherence questionnaire 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment
Primary Cardiac anxiety questionnaire modified for weekly assessment Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety. Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment [PRIMARY ENDPOINT]
Secondary Cardiac anxiety questionnaire Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety. From baseline to 8 months
Secondary Cardiac anxiety questionnaire Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety. From baseline to 1 year and 2 months
Secondary HeartQoL Health-related Quality of Life Questionnaire modified for weekly assessment The HeartQoL questionnaire, comprising 14 items, includes a Global scale of 14 items, further divided into Physical (10 items) and Emotional (4 items) subscales. Scores range from 0 to 3, with 3 indicating the highest level and 0 the lowest. Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment
Secondary HeartQoL Health-related Quality of Life Questionnaire The HeartQoL questionnaire, comprising 14 items, includes a Global scale of 14 items, further divided into Physical (10 items) and Emotional (4 items) subscales. Scores range from 0 to 3, with 3 indicating the highest level and 0 the lowest. From baseline to 8 months
Secondary HeartQoL Health-related Quality of Life Questionnaire The HeartQoL questionnaire, comprising 14 items, includes a Global scale of 14 items, further divided into Physical (10 items) and Emotional (4 items) subscales. Scores range from 0 to 3, with 3 indicating the highest level and 0 the lowest. From baseline to 1 year and 2 months
Secondary Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease) modified for weekly assessment Cardiac-related symptoms in two sub scales A) frequency: score ranging from 0-48, with higher score indicating higher frequency of symptoms, B) severity of experienced symptom: score ranging from 0- 48, with a higher score indicating more severe symptoms From baseline to 8 weeks
Secondary Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease) cardiac-related symptoms in two sub scales A) frequency: score ranging from 0-48, with higher score indicating higher frequency of symptoms, B) severity of experienced symptom: score ranging from 0- 48, with a higher score indicating more severe symptoms From baseline to 8 months
Secondary Symptom checklist Severity and Frequency Scale (SCL, adapted to coronary artery disease) Cardiac-related symptoms in two sub scales A) frequency: score ranging from 0-48, with higher score indicating higher frequency of symptoms, B) severity of experienced symptom: score ranging from 0- 48, with a higher score indicating more severe symptoms From baseline to 1 year and 2 months
Secondary University of Toronto Atrial fibrillation Severity Scale (AFSS) 3 item on cardiac-specific healthcare consumption. Scores ranges 0-15 with a higher score indicating more cardiac-related healthcare consumption Baseline to 8 weeks
Secondary University of Toronto Atrial fibrillation Severity Scale (AFSS) 3 item on cardiac-specific healthcare consumption. Scores ranges 0-15 with a higher score indicating more cardiac-related healthcare consumption From baseline to 8 months
Secondary University of Toronto Atrial fibrillation Severity Scale (AFSS) 3 item on cardiac-specific healthcare consumption. Scores ranges 0-15 with a higher score indicating more cardiac-related healthcare consumption From baseline to 1 year and 2 months
Secondary Myocardial infarction behavior questionnaire MI-related avoidance questionnaire behaviors developed by the research group From baseline to 8 weeks
Secondary Myocardial infarction behavior questionnaire MI-related avoidance questionnaire behaviors developed by the research group From baseline to 8 months
Secondary Myocardial infarction behavior questionnaire MI-related avoidance questionnaire behaviors developed by the research group From baseline to 1 year and 2 months
Secondary DOSE Non-Adherence questionnaire 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. From baseline to 8 weeks
Secondary DOSE Non-Adherence questionnaire 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. From baseline to 8 months
Secondary DOSE Non-Adherence questionnaire 3 items from this two domain scale measuring medical adherence designed to assess missed doses and reasons for missed doses. From baseline to 1 year and 2 months
Secondary Perceived stress scale 4-item Stress reactivity. A greater score indicate more perceived stress. Baseline to 8 weeks
Secondary Perceived stress scale 4-item Stress reactivity. A greater score indicate more perceived stress. Baseline to 8 months
Secondary Perceived stress scale 4-item Stress reactivity. A greater score indicate more perceived stress. Baseline to 1 year and 2 months
Secondary Short Fatigue questionnaire 4-item scale measuring fatigue. From baseline to 8 weeks
Secondary Short Fatigue questionnaire 4-item scale measuring fatigue. Baseline to 8 months
Secondary Short Fatigue questionnaire 4-item scale measuring fatigue. Baseline to 1 year and 2 months
Secondary Patient Health Questionnaire-9 Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression From Baseline to 8 weeks
Secondary Patient Health Questionnaire-9 Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression From Baseline to 8 months
Secondary Patient Health Questionnaire-9 Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression From Baseline to 1 year and 2 months
Secondary Insomnia Severity Index Measurement of the degree of sleep difficulties. The total score can range from 0 to 28 points. Higher scores indicate more severe sleep difficulties. From Baseline to 8 weeks
Secondary Insomnia Severity Index Measurement of the degree of sleep difficulties. The total score can range from 0 to 28 points. Higher scores indicate more severe sleep difficulties. From Baseline to 8 months
Secondary Insomnia Severity Index Measurement of the degree of sleep difficulties. The total score can range from 0 to 28 points. Higher scores indicate more severe sleep difficulties. From Baseline to 1 year and 2 months
Secondary Perceived stress scale 4-item Stress reactivity. A greater score indicate more perceived stress. Change over 9 measurement points measured from baseline and weekly for 8 weeks during treatment
Secondary The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity Level of physical activity and inactivity: On the Godin leisure-time excercise: The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity. And from International Physical Activity Questionnaire we will use 1 item on inactivity Baseline to 8 weeks
Secondary The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity Level of physical activity and inactivity: On the Godin leisure-time excercise: The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity. And from International Physical Activity Questionnaire we will use 1 item on inactivity Baseline to 8 months
Secondary The Godin Leisure-time Exercise and International Physical Activity Questionnaire 1 item on inactivity Level of physical activity and inactivity: On the Godin leisure-time excercise: The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity. And from International Physical Activity Questionnaire we will use 1 item on inactivity Baseline to 1 year and 2 months
Secondary Lifestyle factors: The national Board of health and Welfare questionnaire Questionnaire regarding diet (5 item), tobacco (2 item) and alcohol (3 item) diet (5 item), tobacco (2 item) and alcohol (3 item) and BMI. Baseline to 8 weeks
Secondary Lifestyle factors: The national Board of health and Welfare questionnaire Questionnaire regarding diet (5 item), tobacco (2 item) and alcohol (3 item) diet (5 item), tobacco (2 item) and alcohol (3 item) and BMI. Baseline to 8 months
Secondary Lifestyle factors: The national Board of health and Welfare questionnaire Questionnaire regarding diet (5 item), tobacco (2 item) and alcohol (3 item) diet (5 item), tobacco (2 item) and alcohol (3 item) and BMI. Baseline to 1 year and 2 months
Secondary Aversive cognition to medication : A 3-item subset of questions with regards to psychological distress associated with cardiac medication Baseline to 8 weeks
Secondary Adversive cognition to medication : A 3-item subset of questions with regards to psychological distress associated with cardiac medication Baseline to 8 months
Secondary Adversive cognition to medication : A 3-item subset of questions with regards to psychological distress associated with cardiac medication Baseline to 1 year and 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study